Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)

Liqiong XUE; Ye GUO; Libo CHEN

doi:10.19401/j.cnki.1007-3639.2023.09.009

您当前的位置：

首页 >

文章列表页 >

Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)

Guideline and concensus | 更新时间：2025-12-31

- Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)
- China Oncology Vol. 33, Issue 9, Pages: 879-888(2023)
- 作者机构：
  
  中国临床肿瘤学会甲状腺癌专家委员会
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.09.009
  CLC： R736.1
- Received：31 July 2023，
  
  Revised：2023-08-19，
  
  Published：30 September 2023
- 稿件说明：
移动端阅览
Liqiong XUE, Ye GUO, Libo CHEN. Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)[J]. China Oncology, 2023, 33(9): 879-888.
DOI：

Liqiong XUE, Ye GUO, Libo CHEN. Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)[J]. China Oncology, 2023, 33(9): 879-888. DOI： 10.19401/j.cnki.1007-3639.2023.09.009.

摘要

近年来，靶向治疗已成为晚期甲状腺癌的标准治疗方法。虽然中国临床肿瘤学会甲状腺癌专家委员会在2018年出版了针对放射性碘难治性分化型甲状腺癌（radioactive iodine-refractory differentiated thyroid cancer，RAIR-DTC）的靶向药物不良反应专家共识，但目前靶向治疗获批的类型已延伸至甲状腺髓样癌（medullary thyroid cancer，MTC）和甲状腺未分化癌（anaplastic thyroid cancer，ATC），靶向药物也从多靶点激酶抑制剂（multikinase inhibitors，MKIs）延伸至BRAF抑制剂、MEK抑制剂、RET抑制剂和TRK抑制剂。随着多种不同作用机制的靶向药物在临床上的广泛应用，并且考虑到众多来自不同科室的医师涉及晚期甲状腺癌的靶向治疗，靶向药物的不良反应管理急需不断规范和完善。因此，中国临床肿瘤学会甲状腺癌专家委员会组织专家组进行深入探讨，共同制定了本专家共识，旨在形成相对规范统一的认识，更好地指导临床实践。

Abstract

Recently

targeted therapy has become the standard of care for advanced thyroid cancer. Although expert consensus on the management of adverse events in patients receiving targeted agents for radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) was formulated by Thyroid Cancer Committee of Chinese Society of Clinical Oncology in 2018

the tumor types which are eligible for targeted therapy have been extended to medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC)

and targeted agents have been approved from multikinase inhibitors (MKIs) to BRAF inhibitors

MEK inhibitors

RET inhibitors and TRK inhibitors. Along with the widely used targeted agents with different mechanism

the management of adverse events for targeted agents needs to be standardized and improved

especially considering the specialties of the physicians who are involved in the targeted therapy for thyroid cancer are variable. Therefore

Thyroid Cancer Committee of Chinese Society of Clinical Oncology convened an expert task force charged with developing consensus to serves as a guidance to standardize utilization of targeted agents and to optimize clinical practice.

关键词

Keywords

references

MILLER K C , CHINTAKUNTLAWAR A V . Molecular-driven therapy in advanced thyroid cancer [J ] . Curr Treat Options Oncol , 2021 , 22 ( 3 ): 24 . DOI: 10.1007/s11864-021-00822-7 http://doi.org/10.1007/s11864-021-00822-7

中国临床肿瘤学会CSCO甲状腺癌专家委员会 . 碘难治性分化型甲状腺癌靶向药物不良反应管理专家共识(2018年版) [J ] . 中国癌症杂志 , 2018 , 28 ( 7 ): 545 - 553 . DOI: 10.19401/j.cnki.1007-3639.2018.07.012 http://doi.org/10.19401/j.cnki.1007-3639.2018.07.012

Thyroid Cancer Committee of Chinese Society of Clinical Oncology . Expert consensus on adverse drug reactions management of iodine refractory differentiated thyroid cancer (2018 edition) [J ] . China Oncol , 2018 , 28 ( 7 ): 545 - 553 .

U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [EB/OL ] . ( 2017-11-27 )[ 2023-06-30 ] . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf

KOMMALAPATI A , TELLA S H , BORAD M , et al . FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice [J ] . Cancers (Basel) , 2021 , 13 ( 12 ): 2968 . DOI: 10.3390/cancers13122968 http://doi.org/10.3390/cancers13122968 https://www.mdpi.com/2072-6694/13/12/2968 https://www.mdpi.com/2072-6694/13/12/2968

Centre for Evidence-Based Medicine . Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) [EB/OL ] . ( 2009-03-01 )[ 2023-06-30 ] . https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009.

FINK A , KOSECOFF J , CHASSIN M , et al . Consensus methods: characteristics and guidelines for use [J ] . Am J Public Health , 1984 , 74 ( 9 ): 979 - 983 . DOI: 10.2105/ajph.74.9.979 http://doi.org/10.2105/ajph.74.9.979

BROSE M S , NUTTING C M , JARZAB B , et al . Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J ] . Lancet , 2014 , 384 ( 9940 ): 319 - 328 . DOI: 10.1016/S0140-6736(14)60421-9 http://doi.org/10.1016/S0140-6736(14)60421-9

ZHENG X Q , XU Z G , JI Q H , et al . A randomized, phase Ⅲ study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer [J ] . Clin Cancer Res , 2021 , 27 ( 20 ): 5502 - 5509 . DOI: 10.1158/1078-0432.CCR-21-0761 http://doi.org/10.1158/1078-0432.CCR-21-0761 https://aacrjournals.org/clincancerres/article/27/20/5502/671674/A-Randomized-Phase-III-Study-of-Lenvatinib-in https://aacrjournals.org/clincancerres/article/27/20/5502/671674/A-Randomized-Phase-III-Study-of-Lenvatinib-in

LIN Y , YANG H , SHI F , et al . Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, placebo-controlled, multi-center phase Ⅲ clinical trial (DIRECTION) [J ] . Ann Oncol , 2022 , 33 ( Suppl_7 ): S1294 .

CHI Y , ZHENG X Q , ZHANG Y , et al . Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase Ⅱ trial [J ] . Clin Cancer Res , 2023 : CCR-C22 - 3406 .

LI D P , CHI Y , CHEN X H , et al . Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial [J ] . Clin Cancer Res , 2021 , 27 ( 13 ): 3567 - 3575 . DOI: 10.1158/1078-0432.CCR-20-2950 http://doi.org/10.1158/1078-0432.CCR-20-2950 https://aacrjournals.org/clincancerres/article/27/13/3567/671471/Anlotinib-in-Locally-Advanced-or-Metastatic https://aacrjournals.org/clincancerres/article/27/13/3567/671471/Anlotinib-in-Locally-Advanced-or-Metastatic

OBA T , CHINO T , SOMA A , et al . Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis [J ] . Endocr J , 2020 , 67 ( 12 ): 1215 - 1226 . DOI: 10.1507/endocrj.EJ20-0171 http://doi.org/10.1507/endocrj.EJ20-0171 https://www.jstage.jst.go.jp/article/endocrj/67/12/67_EJ20-0171/_article https://www.jstage.jst.go.jp/article/endocrj/67/12/67_EJ20-0171/_article

LI L Y , CHENG L , SA R , et al . Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers [J ] . Crit Rev Oncol Hematol , 2022 , 172 : 103624 . DOI: 10.1016/j.critrevonc.2022.103624 http://doi.org/10.1016/j.critrevonc.2022.103624 https://linkinghub.elsevier.com/retrieve/pii/S1040842822000488 https://linkinghub.elsevier.com/retrieve/pii/S1040842822000488

U.S. Food and Drug Administration . FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation [EB/OL ] . ( 2022-06-23 )[ 2023-06-30 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unre sectable-or-metastatic-solid.

SUBBIAH V , KREITMAN R J , WAINBERG Z A , et al . Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study [J ] . Ann Oncol , 2022 , 33 ( 4 ): 406 - 415 . DOI: 10.1016/j.annonc.2021.12.014 http://doi.org/10.1016/j.annonc.2021.12.014 https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059 https://linkinghub.elsevier.com/retrieve/pii/S0923753422000059

BUSAIDY N L , KONDA B , WEI L , et al . Dabrafenib versus dabrafenib+trametinib in BRAF -mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial [J ] . Thyroid , 2022 , 32 ( 10 ): 1184 - 1192 .

GAO M , ZHENG X , WANG Y , et al . Efficacy and safety of pralsetinib, a selective RET inhibitor, in Chinese patients with advanced RET -mutant medullary thyroid cancer [C ] . Thyroid , 2021 , 31 ( Suppl_1 ): abstract LBO 3.

ZHENG X Q , JI Q H , SUN Y P , et al . Efficacy and safety of selpercatinib in Chinese patients with advanced RET -altered thyroid cancers: results from the phase Ⅱ LIBRETTO-321 study [J ] . Ther Adv Med Oncol , 2022 , 14 : 17588359221119318.

CABANILLAS M E , LIN J J , BROSE M S , et al . Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC) [J ] . J Clin Oncol , 2023 , 41 ( Suppl_16 ): 6091 . DOI: 10.1200/JCO.2023.41.16_suppl.6091 http://doi.org/10.1200/JCO.2023.41.16_suppl.6091 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.6091 https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.6091

KRZAKOWSKI M J , LU S , COUSIN S , et al . Updated analysis of the efficacy and safety o f entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive ( NTRK -fp) solid tumors [J ] . J Clin Oncol , 2022 , 40 ( Suppl_16 ): 3099 .

DOEBELE R C , DRILON A , PAZ-ARES L , et al . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [J ] . Lancet Oncol , 2020 , 21 ( 2 ): 271 - 282 . DOI: S1470-2045(19)30691-6 http://doi.org/S1470-2045(19)30691-6

REED N , GLEN H , GERRARD G , et al . Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer [J ] . Clin Oncol (R Coll Radiol) , 2020 , 32 ( 5 ): e145 - e153 . DOI: 10.1016/j.clon.2019.11.010 http://doi.org/10.1016/j.clon.2019.11.010

LYON A R , LÓPEZ-FERNÁNDEZ T , COUCH L S , et al . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [J ] . Eur Heart J , 2022 , 43 ( 41 ): 4229 - 4361 . DOI: 10.1093/eurheartj/ehac244 http://doi.org/10.1093/eurheartj/ehac244

MCLELLAN B , CIARDIELLO F , LACOUTURE M E , et al . Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management [J ] . Ann Oncol , 2015 , 26 ( 10 ): 2017 - 2026 . DOI: 10.1093/annonc/mdv244 http://doi.org/10.1093/annonc/mdv244

REN Z G , ZHU K S , KANG H Y , et al . Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma [J ] . J Clin Oncol , 2015 , 33 ( 8 ): 894 - 900 . DOI: 10.1200/JCO.2013.52.9651 http://doi.org/10.1200/JCO.2013.52.9651

WORDEN F , FASSNACHT M , SHI Y K , et al . Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer [J ] . Endocr Relat Cancer , 2015 , 22 ( 6 ): 877 - 887 . DOI: 10.1530/ERC-15-0252 http://doi.org/10.1530/ERC-15-0252 https://erc.bioscientifica.com/view/journals/erc/22/6/877.xml https://erc.bioscientifica.com/view/journals/erc/22/6/877.xml

HADDAD R I , SCHLUMBERGER M , WIRTH L J , et al . Incidence and timing of common adverse events in lenvatinib-treated patients from the SELECT trial and their association with survival outcomes [J ] . Endocrine , 2017 , 56 ( 1 ): 121 - 128 . DOI: 10.1007/s12020-017-1233-5 http://doi.org/10.1007/s12020-017-1233-5

KIYOTA N , SCHLUMBERGER M , MURO K , et al . Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer [J ] . Cancer Sci , 2015 , 106 ( 12 ): 1714 - 1721 . DOI: 10.1111/cas.2015.106.issue-12 http://doi.org/10.1111/cas.2015.106.issue-12 https://onlinelibrary.wiley.com/toc/13497006/106/12 https://onlinelibrary.wiley.com/toc/13497006/106/12

SCHLUMBERGER M , TAHARA M , WIRTH L J , et al . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer [J ] . N Engl J Med , 2015 , 372 ( 7 ): 621 - 630 . DOI: 10.1056/NEJMoa1406470 http://doi.org/10.1056/NEJMoa1406470 http://www.nejm.org/doi/10.1056/NEJMoa1406470 http://www.nejm.org/doi/10.1056/NEJMoa1406470

NERVO A , RETTA F , RAGNI A , et al . Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update [J ] . Crit Rev Oncol Hematol , 2021 , 168 : 103533 . DOI: 10.1016/j.critrevonc.2021.103533 http://doi.org/10.1016/j.critrevonc.2021.103533 https://linkinghub.elsevier.com/retrieve/pii/S1040842821003206 https://linkinghub.elsevier.com/retrieve/pii/S1040842821003206

SCHADENDORF D , ROBERT C , DUMMER R , et al . Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF -mutant cancers [J ] . Eur J Cancer , 2021 , 153 : 234 - 241 . DOI: 10.1016/j.ejca.2021.05.005 http://doi.org/10.1016/j.ejca.2021.05.005 https://linkinghub.elsevier.com/retrieve/pii/S0959804921003038 https://linkinghub.elsevier.com/retrieve/pii/S0959804921003038

ATKINSON V , LONG G V , MENZIES A M , et al . Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists [J ] . Asia Pac J Clin Oncol , 2016 , 12 ( Suppl 7 ): 5 - 12 .

ATKINSON V , ROBERT C , GROB J J , et al . Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: primary results of COMBI-APlus [J ] . Eur J Cancer , 2022 , 163 : 79 - 87 . DOI: 10.1016/j.ejca.2021.12.015 http://doi.org/10.1016/j.ejca.2021.12.015

SUBBIAH V , HU M I , WIRTH L J , et al . Pralsetinib for patients with advanced or metastatic RET -altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study [J ] . Lancet Diabetes Endocrinol , 2021 , 9 ( 8 ): 491 - 501 . DOI: 10.1016/S2213-8587(21)00120-0 http://doi.org/10.1016/S2213-8587(21)00120-0 https://linkinghub.elsevier.com/retrieve/pii/S2213858721001200 https://linkinghub.elsevier.com/retrieve/pii/S2213858721001200

YIMAER W , ABUDOUYIMU A , TIAN Y , et al . Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials [J ] . Onco Targets Ther , 2016 , 9 : 1167 - 1173 .

Views

2993

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Expert consensus on diagnosis and treatment of hematologic malignancies with solid tumors (2025 version)

Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)

Research progress on treatment of pleural effusion related to immune checkpoint inhibitors

Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy (2024 edition)

Related Author

Chenping ZHANG

Chaosu HU

Ye GUO

Rare Disease Group, Hematology Branch, Chinese Medical Association

Lymphocytic Disease Group, Hematology Branch, Chinese Medical Association

Shanghai Anti Cancer Association Multiple Primary and Unknown Primary Tumor Special Committee

Multiple Primary and Unknown Primary Tumors Special Committee of China Anti-Cancer Association

Liqiong XUE

Related Institution

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Institute of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

Gynecologic Oncology Genetic Counseling Collaboration Group, Chinese Tertiary Obstetrics and Gynecology Hospital/Materning and Child Healthcare Hospital Alliance; Integrated Chinese and Western Endometrial Cancer Professional Committee, Chinese Anti-Cancer Association

上海交通大学附属第六人民医院核医学科

AI问答

⁰